scholarly journals Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

Kidney Cancer ◽  
2019 ◽  
Vol 3 (1) ◽  
pp. 51-61 ◽  
Author(s):  
Thomas J Semrad ◽  
Susan Groshen ◽  
Chunqiao Luo ◽  
Sumanta Pal ◽  
Ulka Vaishampayan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Vascular Endothelial ◽  
Phase 2 ◽  
Amg 386 ◽  
Phase 2 Study ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor ◽  
Randomized Phase 2

scholarly journals Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Bo Zhao ◽  
Laura S. Wood ◽  
Karen James ◽  
Brian I. Rini
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cardiac Ischemia ◽  
Vascular Endothelial ◽  
Cardiac Events ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.

Sign in / Sign up

Export Citation Format

Share Document